Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$1.69
+0.9%
$1.73
$1.41
$5.01
$9.27M1.2225,886 shs42,645 shs
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
$1.59
+3.9%
$0.88
$0.65
$26.25
$16.27M0.87729,774 shs2.67 million shs
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
$0.00
$0.00
$0.00
$0.00
$710K-0.2144,492 shs5,000 shs
Talphera, Inc. stock logo
TLPH
Talphera
$0.46
-1.7%
$0.49
$0.43
$1.19
$9.60M-0.1170,722 shs46,244 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
+0.90%+5.62%-5.06%-11.98%-58.48%
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
+3.92%+54.37%+129.97%+32.50%-89.10%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00%0.00%0.00%-50.00%0.00%
Talphera, Inc. stock logo
TLPH
Talphera
-1.67%+4.59%-4.14%-13.17%-48.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
3.4172 of 5 stars
3.54.00.00.01.92.51.3
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2.6769 of 5 stars
3.42.00.00.03.10.81.3
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Talphera, Inc. stock logo
TLPH
Talphera
2.7183 of 5 stars
3.83.00.00.03.30.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
3.00
Buy$15.50817.16% Upside
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2.80
Moderate Buy$53.003,233.33% Upside
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00
N/AN/AN/A
Talphera, Inc. stock logo
TLPH
Talphera
3.50
Strong Buy$5.00986.48% Upside

Current Analyst Ratings Breakdown

Latest NPHC, APRE, TLPH, and CTXR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00
6/26/2025
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$11.00
6/9/2025
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
5/23/2025
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/23/2025
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/15/2025
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
4/1/2025
Talphera, Inc. stock logo
TLPH
Talphera
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$1.50M6.23N/AN/A$3.55 per share0.48
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/AN/AN/AN/A$10.25 per shareN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/A
Talphera, Inc. stock logo
TLPH
Talphera
$650K14.51N/AN/A$0.47 per share0.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$12.96M-$2.37N/AN/AN/A-1,095.02%-68.39%-55.74%8/11/2025 (Estimated)
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-$39.14MN/A0.001.27N/AN/A-58.63%-37.67%8/11/2025 (Estimated)
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/A0.00N/AN/AN/AN/AN/A
Talphera, Inc. stock logo
TLPH
Talphera
-$13M-$0.45N/AN/AN/AN/A-130.28%-59.25%8/13/2025 (Estimated)

Latest NPHC, APRE, TLPH, and CTXR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.6543-$0.66-$0.0057-$0.66N/A$0.16 million
5/14/2025Q2 2025
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-$1.08-$1.27-$0.19-$1.27N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/AN/AN/AN/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/AN/AN/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/A
Talphera, Inc. stock logo
TLPH
Talphera
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/A
5.90
5.90
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/A
0.37
0.06
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/A
Talphera, Inc. stock logo
TLPH
Talphera
N/A
3.11
3.11

Institutional Ownership

CompanyInstitutional Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
34.19%
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
16.88%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/A
Talphera, Inc. stock logo
TLPH
Talphera
37.67%

Insider Ownership

CompanyInsider Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
13.63%
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
10.70%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
61.50%
Talphera, Inc. stock logo
TLPH
Talphera
3.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
75.53 million4.78 millionNo Data
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2010.63 million9.50 millionOptionable
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
47.10 billion2.73 billionNot Optionable
Talphera, Inc. stock logo
TLPH
Talphera
1920.50 million19.85 millionOptionable

Recent News About These Companies

Talphera reports Q4 EPS (7c) vs. (25c) last year
Talphera announces agreement with FDA to reduce NEPHRO CRRT study size
Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript
7TLPH : Earnings Outlook For Talphera

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aprea Therapeutics stock logo

Aprea Therapeutics NASDAQ:APRE

$1.69 +0.02 (+0.90%)
As of 06/30/2025 03:59 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Citius Pharmaceuticals stock logo

Citius Pharmaceuticals NASDAQ:CTXR

$1.59 +0.06 (+3.92%)
As of 06/30/2025 04:00 PM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Nutra Pharma stock logo

Nutra Pharma OTCMKTS:NPHC

$0.0001 0.00 (0.00%)
As of 06/27/2025 10:45 AM Eastern

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

Talphera stock logo

Talphera NASDAQ:TLPH

$0.46 -0.01 (-1.67%)
As of 06/30/2025 03:50 PM Eastern

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.